OncoMatch/Clinical Trials/NCT06088030

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Is NCT06088030 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Arsenic trioxide for pediatric cancer.

Phase 2RecruitingYang LiNCT06088030Data as of Jun 2026Location: China

Treatment: Arsenic trioxide — This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Arsenic trioxide

Biomarker criteria

Required: TP53 mutation

Demographics

Ages ≤ 18

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06088030 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require TP53?

Yes, TP53 mutation is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 18 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify